Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova
LaNova's PD-1xVEGF bispecific antibody was licensed to Merck in a $588 million upfront deal.
Angus Liu
Jul 15, 2025 10:16am
China biotechs ‘reshaping’ US biopharma: Jefferies report
Jul 14, 2025 2:30pm
Merck wades deeper into HIV PrEP waters with pair of trials
Jul 14, 2025 1:12pm
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Jun 13, 2025 8:00am
Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3
Jun 9, 2025 9:00am
Merck made $3B offer for MoonLake—and could revive interest: FT
Jun 3, 2025 9:25am
